t+ medical ltd - clinical trial portfolio
DESCRIPTION
Have a look at our excellent portfolio of clinical trials. http://www.tplusmedical.comTRANSCRIPT
![Page 1: t+ Medical Ltd - Clinical Trial Portfolio](https://reader033.vdocuments.site/reader033/viewer/2022052505/5567c50fd8b42a2c098b457c/html5/thumbnails/1.jpg)
Clinical Trial Portfolio
![Page 2: t+ Medical Ltd - Clinical Trial Portfolio](https://reader033.vdocuments.site/reader033/viewer/2022052505/5567c50fd8b42a2c098b457c/html5/thumbnails/2.jpg)
2Company Confidential © t+Medical 2002-2006
Clinical Trial Portfolio
• Asthma (O2, Isle of Mann DoH): – Observational study of 100 asthmatics in 9 GP surgeries in Thames Valley, ended Jan 2004– Surgery based trial of t+ asthma in Isle of Man, ending Nov 2005
• Diabetes type 1 (Vodafone): – Full RCT of 93 Type 1 patients in Oxford ended Jan 2005
• Diabetes type 2 (Lloyds pharmacy):– Observational study of type 2 patients in 3 pharmacies in Oxford area. Ending Nov 2005
• Cystic fibrosis (O2):– Observational study of 60 CF patients at Bristol Royal Infirmary ending July 2006
• Oncology trial (Vodafone, Roche and Aventis):– 400-patient multi-centre trial starting Nov 2005 (early detection of high toxicity and/or
infection with new chemotherapy drugs)• COPD (O2):
– Observational study of 40 COPD patients at BRI, start Nov 2005• Diabetes Titration (SFR)
– Observation study of 20 titration patients with AFD in France
![Page 3: t+ Medical Ltd - Clinical Trial Portfolio](https://reader033.vdocuments.site/reader033/viewer/2022052505/5567c50fd8b42a2c098b457c/html5/thumbnails/3.jpg)
A randomized controlled trial of the effect of real-time telemedicine support on glycaemic control in young adults with type 1 diabetes
Diabetes and Vascular Disease Group
Department of Primary Health Care, University of Oxford
Department of Engineering Science University of Oxford
The Oxford Diabetes Type 1 clinical trial
![Page 4: t+ Medical Ltd - Clinical Trial Portfolio](https://reader033.vdocuments.site/reader033/viewer/2022052505/5567c50fd8b42a2c098b457c/html5/thumbnails/4.jpg)
4Company Confidential © t+Medical 2002-2006
Changes in HbA1c over 9 months
8.0
8.2
8.4
8.6
8.8
9.0
9.2
9.4
Baseline 4 months 9 months
Control
Intervention
HbA
1c (%
)
0.6%, P=0.0001
0.4%, P=0.04
0.2%, P=0.3
Recorded Improvement in HbA1c = 0.7 % points or 8% in 9 months
![Page 5: t+ Medical Ltd - Clinical Trial Portfolio](https://reader033.vdocuments.site/reader033/viewer/2022052505/5567c50fd8b42a2c098b457c/html5/thumbnails/5.jpg)
5Company Confidential © t+Medical 2002-2006
450 % increase in proportion achieving HbA1c ≤ 8%
0
5
10
15
20
25
30
35
40
45
50
Baseline 9 months
Control
Intervention
% H
bA1c
≤ 8
%
Difference in change in proportions - P=0.0002
![Page 6: t+ Medical Ltd - Clinical Trial Portfolio](https://reader033.vdocuments.site/reader033/viewer/2022052505/5567c50fd8b42a2c098b457c/html5/thumbnails/6.jpg)
6Company Confidential © t+Medical 2002-2006
Type II Diabetes Study
• Poorly-controlled patients (HbA1c > 8%) are brought under control through using t+ diabetes
• Well-controlled patients (HbA1c < 7.4%) remain well controlled
Entry Exit0
1
2
3
4
5
6
7
8
9
10
11
HbA
1c (
%)
HbA1c at entry and exit
Mean age = 58 years (oldest patient was 81 years old) Mean HbA1c at entry = 7.5%; mean HbA1c at exit = 6.8%
![Page 7: t+ Medical Ltd - Clinical Trial Portfolio](https://reader033.vdocuments.site/reader033/viewer/2022052505/5567c50fd8b42a2c098b457c/html5/thumbnails/7.jpg)
7Company Confidential © t+Medical 2002-2006
Asthma Solution• Peak flow data recorded and shared in supervised log• Adverse trends sets of alerts to medical personnel or family.• Additional web based notifications alerts patient to changes in climate etc.
![Page 8: t+ Medical Ltd - Clinical Trial Portfolio](https://reader033.vdocuments.site/reader033/viewer/2022052505/5567c50fd8b42a2c098b457c/html5/thumbnails/8.jpg)
8Company Confidential © t+Medical 2002-2006
Clinical Trial Outcomes• Thames Valley Asthma Study 91 Patient 6 month study on impact of t+
system
93% delivered one reading per day 74% indicated that it helped them overcome
symptoms 32% reduction in inhaler use
![Page 9: t+ Medical Ltd - Clinical Trial Portfolio](https://reader033.vdocuments.site/reader033/viewer/2022052505/5567c50fd8b42a2c098b457c/html5/thumbnails/9.jpg)
9Company Confidential © t+Medical 2002-2006
• Pilot study in France sponsored by SFR• Clinical partners: AFD (French Diabetic
Association) and Centre Hospitalier de Corbeilles-Essonnes (Dr Charpentier)
• 3-month study with 10 patients to be titrated• N=200 study in design
t+ diabetes for insulin titration
![Page 10: t+ Medical Ltd - Clinical Trial Portfolio](https://reader033.vdocuments.site/reader033/viewer/2022052505/5567c50fd8b42a2c098b457c/html5/thumbnails/10.jpg)
10Company Confidential © t+Medical 2002-2006
Patient 1 Titration – all BG data
2 month titration including vacation